Company

Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new drug class for unmet medical needs in cardiovascular disease, including high blood pressure and heart failure.

Quantum Genomics research programs are based on the brain inhibition mechanism of Aminopeptidase A : BAPAI (Brain Aminopeptidase A Inhibitors), a truly innovative triple-action therapeutic platform developed by the academic research laboratories of the Collège de France and INSERM.

Quantum Genomics is the only biopharmaceutical company specializing in the development of a new drug class based on the central action mechanism of Aminopeptidase A inhibition.

Quantum Genomics is the only biopharmaceutical company specializing in the development of a new drug class based on the central action mechanism of Aminopeptidase A inhibition.

Research programs

  • Development of firibastat, First-in-Class for the treatment of high blood pressure
  • Development of firibastat in combination with others anti-hypertensive drugs
  • Development of Best-in-Class drugs for the treatment of high blood pressure as monotherapy and the prevention and treatment of heart failure